Clinicopathological significance of mutation profile detected by next generation sequencing in different metastatic organs of non-small cell lung cancers
Pathology - Research and Practice · 2024
DOI: 10.1016/j.prp.2024.155463 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathology - Research and Practice, 2024. Verfasst von Dilara Akın und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Aydın Adnan Menderes University Faculty of Medicine, Aydın, Turkey. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, High-Throughput Nucleotide Sequencing, Mutation. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 48 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: The primary tumor and it's metastases show heterogeneity in molecular studies for targeted therapies in Non-Small Cell Lung Cancer(NSCLC), the leading cause of cancer-related deaths worldwide. The study aimed to identify somatic mutations in biopsies from NSCLC patients' metastatic organs using Next-Generation Sequencing(NGS) and examine their association with clinicopathological parameters. MATERIALS AND METHODS: The study included 128 NSCLC patients and, NGS was performed on tumor biopsies from different metastatic organs at Molecular Pathology laboratory of the Department of Medical Pathology in Aydın Adnan Menderes University Faculty of Medicine. The age, gender, histopathological diagnoses, metastatic organs, smoking and mutation status were all recorded, along with the analysis results of 72 genes and 4149 primers in the panel of the NGS system. RESULTS: 53.9 % of the cases had a history of smoking and patients with brain metastases had a higher smoking rate(p=0.000). The most common occurrence(39.8 %) was lymph node metastasis, followed by brain(19.5 %). There was a strong correlation between mutation presence and metastasis in the liver(p=0.012), bone(p=0.002), and pleura(p=0.008). Smokers had a higher frequency of KRAS(p=0.000) and TP53(p=0.001) mutations. Brain metastases showed a statistically significant NF1 mutation(p=0.001), while the liver exhibited a significant BRAF mutation(p=0.000). NF1-TP53, PTEN-TP53 and NF1-PTEN were the most common concomitant mutations and, the brain was the most common metastatic organ in which they occurred. CONCLUSION: Our results suggest prizing assessing detected mutations, in the prediction, follow-up and management of metastases, especially in patients with lung adenocarcinoma. The assessment also needs to consider the tumor's mutation status in metastatic organs. New therapeutic agents targeting NF1 mutations will be available in the future to treat NSCLC, especially in metastases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Aydın Adnan Menderes University Faculty of Medicine, Aydın, Turkey.
- Department of Pathology, Aydın Adnan Menderes University Faculty of Medicine, Aydın, Turkey. Electronic address: n.k.cetin@hotmail.com.
- Department of Biostatistics, Aydın Adnan Menderes University Faculty of Medicine, Aydın, Turkey.
Zitieren
APA
Akın, D., Kahraman Çeti N, N., Erdoğdu, İ. H., Öztürk, H., & Meteoğlu, İ. (2024). Clinicopathological significance of mutation profile detected by next generation sequencing in different metastatic organs of non-small cell lung cancers. Pathology - Research and Practice. https://doi.org/10.1016/j.prp.2024.155463
Vancouver
Akın D, Kahraman Çeti N N, Erdoğdu İH, Öztürk H, Meteoğlu İ. Clinicopathological significance of mutation profile detected by next generation sequencing in different metastatic organs of non-small cell lung cancers. Pathology - Research and Practice. 2024. doi:10.1016/j.prp.2024.155463
BibTeX
@article{Akn2024,
author = {Akın, Dilara and Kahraman Çeti N, Nesibe and Erdoğdu, İbrahim Halil and Öztürk, Hakan and Meteoğlu, İbrahim},
title = {Clinicopathological significance of mutation profile detected by next generation sequencing in different metastatic organs of non-small cell lung cancers},
journal = {Pathology - Research and Practice},
year = {2024},
doi = {10.1016/j.prp.2024.155463}
}
EUVIMED